Previous close | 37.75 |
Open | 37.75 |
Bid | 45.80 |
Ask | 48.65 |
Strike | 85.00 |
Expiry date | 2025-12-19 |
Day's range | 37.75 - 37.75 |
Contract range | N/A |
Volume | |
Open interest | 103 |
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma